ArticleAmyotrophic lateral sclerosis & frontotemporal degeneration2019
Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010-2015.
Article in Amyotrophic lateral sclerosis & frontotemporal degeneration, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Pooled it
- Multidisciplinary clinic attendance and patterns of care in the U.S. National ALS Registry, 2013-2023.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2026Article
- Metabolomic analyses of amyotrophic lateral sclerosis, muscle cramps, and TJ-68 treatment.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Elevated serum trimethylamine N-oxide (TMAO) and trimethyllysine in patients with amyotrophic lateral sclerosis (ALS): An exploratory case-control study.IBRO neuroscience reports · 2026Article
- Cutting-edge treatments in amyotrophic lateral sclerosis: the role of molecular pathogenesis in targeted therapies.Stem cell research & therapy · 2025Review
- Racial Disparities in the Diagnosis and Prognosis of ALS Patients in the United States.Journal of racial and ethnic health disparities · 2025Article
- The Impact of Respiratory Function on Functionality and Mortality in ALS Patients.Journal of clinical medicine · 2025Article
- Comparison of Demographics: National Amyotrophic Lateral Sclerosis Registry and Clinical Trials Data.Journal of racial and ethnic health disparities · 2025Article
- Predictive Analysis of Amyotrophic Lateral Sclerosis Progression and Mortality in a Clinic Cohort From Singapore.Muscle & nerve · 2025Article
- Head Injury and Amyotrophic Lateral Sclerosis: Population-Based Study from the National ALS Registry.Brain sciences · 2025Article
- Clinical phenotypes of motor neurone disease in a Kenyan hospital-based population.Frontiers in neurology · 2025Article
- Age-period-cohort effect on motor neuron disease mortality in the United States, 2001-2020.Frontiers in neurology · 2025Article
- Non-motor symptoms in motor neuron disease: prevalence, assessment and impact.Brain communications · 2024Article
- Edaravone administration and its potential association with a new clinical syndrome in cerebral infarction patients: Three case reports.World journal of clinical cases · 2023Article
- Profiles of Dysarthria and Dysphagia in Individuals With Amyotrophic Lateral Sclerosis.Journal of speech, language, and hearing research : JSLHR · 2023Article
- Mesenchymal stem cell therapy in amyotrophic lateral sclerosis (ALS) patients: A comprehensive review of disease information and future perspectives.Iranian journal of basic medical sciences · 2023Review
- Old age amyotrophic lateral sclerosis and limbic TDP-43 pathology.Brain pathology (Zurich, Switzerland) · 2022Article
- Impact of the National Amyotrophic Lateral Sclerosis Registry: Analysis of Registry-funded Research.Annals of clinical and translational neurology · 2022Article
- Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis.EClinicalMedicine · 2022Article
- Analysis of the US Safety Data for Edaravone (RadicavaDrugs in R&D · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.